Definitive Healthcare (NASDAQ:DH) Updates Q2 2024 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) updated its second quarter 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.080-0.090 for the period, compared to the consensus earnings per share estimate of 0.090. The company issued revenue guidance of $62.0 million-$63.5 million, compared to the consensus revenue estimate of $65.2 million. Definitive Healthcare also updated its FY 2024 guidance to 0.360-0.380 EPS.

Definitive Healthcare Stock Performance

NASDAQ DH traded down $0.18 during mid-day trading on Thursday, reaching $5.17. 3,323,524 shares of the stock were exchanged, compared to its average volume of 643,916. The company has a market capitalization of $608.97 million, a P/E ratio of -2.90, a P/E/G ratio of 6.12 and a beta of 1.41. Definitive Healthcare has a 1 year low of $4.38 and a 1 year high of $12.45. The business’s 50 day moving average is $7.61 and its 200-day moving average is $8.27. The company has a debt-to-equity ratio of 0.20, a quick ratio of 2.31 and a current ratio of 2.31.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Wednesday, February 28th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.02). The business had revenue of $65.93 million during the quarter, compared to analysts’ expectations of $66.01 million. Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. On average, equities research analysts forecast that Definitive Healthcare will post 0.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DH has been the subject of several analyst reports. Morgan Stanley cut Definitive Healthcare from an overweight rating to an equal weight rating and dropped their target price for the company from $11.50 to $9.00 in a report on Wednesday. Stifel Nicolaus dropped their price objective on shares of Definitive Healthcare from $11.00 to $9.50 and set a buy rating for the company in a report on Wednesday. Canaccord Genuity Group reduced their target price on shares of Definitive Healthcare from $10.00 to $8.00 and set a hold rating on the stock in a research note on Wednesday. Barclays dropped their price target on shares of Definitive Healthcare from $11.00 to $7.00 and set an equal weight rating for the company in a research note on Thursday. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on shares of Definitive Healthcare from $10.00 to $7.00 and set a hold rating on the stock in a research report on Thursday. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of Hold and a consensus target price of $9.94.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.